Gilead taps brakes on $4.9B bet after rival's failure, pushing blood cancer data out to 2022

Gilead’s $4.9 billion bet on Forty Seven has run into a delay. Weeks after Takeda’s rival drug flunked a pivotal trial, Gilead has pushed back the release of data from a phase 1b study designed to support accelerated approval.

The data drop on magrolimab in the blood cancer myelodysplastic syndrome (MDS), which was scheduled for this year, is now penciled in (PDF) for the first quarter of 2022. Analysts at Jefferies said the delay is “in part due to GILD still talking to FDA on filing requirements, particularly after Takeda just failed a Phase III in MDS after strong Phase IB CR rates in MDS.”